| Year |
Title |
Altmetric |
| 2022
|
Neuropsychiatric features of Prader–Willi syndrome.
American Journal of Medical Genetics Part A.
188:1457-1463.
2022
|
|
| 2022
|
Thrombosis Risk History and D-dimer Levels in Asymptomatic Individuals with Prader–Willi Syndrome.
Journal of Clinical Medicine.
11.
2022
|
|
| 2022
|
The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and Psychometric Validation.
Value in Health.
2022
|
|
| 2021
|
Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium.
Journal of Neurodevelopmental Disorders.
13.
2021
|
|
| 2021
|
Incidence of strabismus, strabismus surgeries, and other vision conditions in Prader-Willi syndrome: data from the Global Prader-Willi Syndrome Registry.
BMC Ophthalmology.
21.
2021
|
|
| 2021
|
Suicidality in individuals with Prader-Willi syndrome: a review of registry survey data.
BMC Psychiatry.
21.
2021
|
|
| 2021
|
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
2021
|
|
| 2021
|
Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome.
PLoS One.
16.
2021
|
|
| 2021
|
Measuring Meaningful Benefit-Risk Tradeoffs to Promote Patient-Focused Drug Development in Prader-Willi Syndrome: A Discrete-Choice Experiment
2021
|
|
| 2020
|
Variability and change over time of weight and BMI among adolescents and adults with Prader-Willi syndrome: A 6-month text-based observational study.
Orphanet Journal of Rare Diseases.
15.
2020
|
|
| 2019
|
The global prader–willi syndrome registry: Development, launch, and early demographics.
Genes.
10.
2019
|
|
| 2018
|
Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best–worst scaling
2018
|
|
| 2018
|
High levels of caregiver burden in Prader-Willi syndrome.
PLoS One.
13.
2018
|
|
| 2018
|
Use of mobile devices to measure outcomes in clinical research, 2010-2016: A systematic literature review.
Digital Biomarkers.
2:11-30.
2018
|
|
| 2017
|
Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use.
Molecular Imaging and Biology.
19:512-521.
2017
|
|
| 2016
|
Prader-Willi syndrome mental health research strategy workshop proceedings: the state of the science and future directions.
Orphanet Journal of Rare Diseases.
11:1-7.
2016
|
|
| 2016
|
The High Direct Medical Costs of Prader-Willi Syndrome.
Journal of Pediatrics.
175:137-143.
2016
|
|
| 2016
|
Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention.
Medical Physics.
43:3143-3156.
2016
|
|
| 2016
|
Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
Journal of Translational Medicine.
14.
2016
|
|
| 2015
|
Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer.
Clinical Cancer Research.
21:3658-3666.
2015
|
|
| 2015
|
Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome..
Diseases.
3:78-85.
2015
|
|
| 2015
|
IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques.
Molecular Imaging and Biology.
17:49-57.
2015
|
|
| 2015
|
Advancing molecular-guided surgery through probe development and testing in a moderate cost evaluation pipeline.
Proceedings of SPIE.
9311.
2015
|
|
| 2009
|
A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.
Vaccine.
27:7116-7124.
2009
|
|
| 2007
|
Whole genome microarray analysis of gene expression in Prader-Willi syndrome.
American Journal of Medical Genetics Part A.
143:430-442.
2007
|
|
| 2006
|
DNA vaccines for cancer.
Frontiers in Bioscience-Landmark.
11:1189-1198.
2006
|
|
| 2006
|
Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands
2006
|
|
| 2005
|
A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).
Vaccine.
23:1273-1283.
2005
|
|
| 2005
|
Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma.
International Journal of Cancer.
113:406-414.
2005
|
|
| 2005
|
Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
Human gene therapy. Clinical development.
16:91-100.
2005
|
|
| 2004
|
Mesothelin: A new target for immunotherapy (multiple letter) [1].
Clinical Cancer Research.
10:8751-8752.
2004
|
|
| 2004
|
Some remarks on the somatic expression of sperm protein 17 [1] (multiple letters).
International Journal of Cancer.
111:972-973.
2004
|
|
| 2004
|
Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.
Human gene therapy. Clinical development.
15:856-864.
2004
|
|
| 2004
|
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer.
International Journal of Cancer.
111:303-309.
2004
|
|
| 2004
|
Characterization of human mesothelin transcripts in ovarian and pancreatic cancer.
BMC Cancer.
4.
2004
|
|
| 2004
|
Expression of sperm protein 17 (Sp17) in ovarian cancer.
International Journal of Cancer.
108:805-811.
2004
|
|
| 2003
|
CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.
Clinical Cancer Research.
9:619-624.
2003
|
|
| 2002
|
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.
Human gene therapy. Clinical development.
13:1505-1514.
2002
|
|
| 2002
|
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Clinical Cancer Research.
8:2782-2787.
2002
|
|
| 2001
|
Expression of human endogenous retrovirus K envelope transcripts in human breast cancer.
Clinical Cancer Research.
7:1553-1560.
2001
|
|
| 2000
|
Gene therapy for carcinoma of the breast genetic immunotherapy.
Breast Cancer Research.
2:15-21.
2000
|
|
| 2000
|
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial.
Clinical Cancer Research.
6:3081-3087.
2000
|
|
| 2000
|
Adenoviral-mediated suicide gene therapy for ovarian cancer.
Molecular Therapy.
2:524-530.
2000
|
|
| 2000
|
Development of a Polynucleotide Vaccine from Melanoma Antigen Recognized by T Cells-1 and Recombinant Protein from Melanoma Antigen Recognized by T Cells-1 for Melanoma Vaccine Clinical Trials.
Journal of Immunotherapy.
23:379-386.
2000
|
|
| 2000
|
Ovarian cancer gene therapy: Repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model.
American Journal of Obstetrics and Gynecology.
182:553-559.
2000
|
|
| 2000
|
SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma.
Cancer Gene Therapy.
7:446-455.
2000
|
|
| 2000
|
Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.
Human gene therapy. Clinical development.
11:1657-1669.
2000
|
|
| 1999
|
Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.
Clinical Cancer Research.
5:2571-2579.
1999
|
|
| 1999
|
Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma.
JAMA Otolaryngology-Head and Neck Surgery.
125:856-863.
1999
|
|
| 1998
|
Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.
Clinical Cancer Research.
4:2903-2912.
1998
|
|
| 1998
|
Cystic fibrosis transmembrane conductance regulator (CFTR) anion binding as a probe of the pore.
Biophysical Journal.
74:1320-1332.
1998
|
|
| 1997
|
CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain..
American Journal of Physiology.
273:L127-L133.
1997
|
|
| 1997
|
Gene therapy strategies for carcinoma of the breast.
Breast Cancer Research and Treatment.
44:93-114.
1997
|
|
| 1997
|
Epithelial localization of a reptilian Na+/H+ exchanger homologous to NHE-1..
American Journal of Physiology.
272:G1594-G1606.
1997
|
|
| 1997
|
Identification of a splice site mutation (2789 + 5 G>A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis.
Human Mutation.
9:332-338.
1997
|
|
| 1997
|
An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2
1997
|
|
| 1997
|
CFTR activation: Additive effects of stimulatory and inhibitory phosphorylation sites in the R domain
1997
|
|
| 1997
|
Epithelial localization of a reptilian Na+/H+ exchanger homologous to NHE-1
1997
|
|
| 1997
|
Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis..
Human Mutation.
9:332-338.
1997
|
|
| 1997
|
Incorporation of β-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression
1997
|
|
| 1996
|
E1A RNA transcripts amplify adenovirus-mediated tumor reduction
1996
|
|
| 1996
|
Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic failure.
Human Mutation.
7:151-154.
1996
|
|
| 1996
|
Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic failure..
Human Mutation.
7:151-154.
1996
|
|
| 1995
|
Missense mutation (G480C) in the CFTR gene associated with protein mislocalization but normal chloride channel activity.
Human Molecular Genetics.
4:269-273.
1995
|
|
| 1994
|
Identification of a CFTR frameshift mutation (1013 delAA) in trans to ΔF508 in a pancreatic sufficient cystic fibrosis patient.
Human Molecular Genetics.
3:2063-2064.
1994
|
|
| 1994
|
Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization.
Journal of Clinical Investigation.
93:347-354.
1994
|
|
| 1993
|
Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR.
Human Molecular Genetics.
2:1253-1261.
1993
|
|
| 1993
|
Expression of an abundant alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a camp-activated chloride conductance.
Human Molecular Genetics.
2:225-230.
1993
|
|
| 1993
|
Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells.
Gastroenterology.
105:1857-1864.
1993
|
|
| 1993
|
Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues.
Nature Genetics.
5:259-265.
1993
|
|
| 1992
|
Characterization of an intron 12 splice donor mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Human Mutation.
1:380-387.
1992
|
|
| 1991
|
Cystic fibrosis gene mutation in two sisters with mild disease and normal sweat electrolyte levels.
New England Journal of Medicine.
325:1630-1634.
1991
|
|
| 1991
|
Evidence for tau expression in cells of monocyte lineage and its in vitro phosphorylation by v-fms kinase.
Oncogene.
6:1085-1087.
1991
|
|
| 1991
|
Two frameshift mutations in the cystic fibrosis gene.
American Journal of Human Genetics.
48:227-231.
1991
|
|
| 1991
|
Chloride conductance expressed by ΔF508 and other mutant CFTRs in xenopus oocytes.
Science.
254:1797-1799.
1991
|
|
| 1990
|
Polyacrylamide gel analysis of polypeptides in gene transfer cell lines.
Somatic Cell and Molecular Genetics.
16:341-349.
1990
|
|
